daklinza
Europe approves BMS hep C drug for HIV and liver transplant patients
February 1, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, daclatasvir, daklinza
The European Commission has approved the expanded use of Bristol Myers-Squibb’s hepatitis C drug Daklinza (daclatasvir), to include liver transplant …
BMS and Medicines Patent Pool collaborate to increase Hep C medicine access
November 25, 2015Manufacturing and Production, Research and Development Bristol-Myers Squibb, Medicines Patent Pool, daclatasvir, daklinza, hepatitis C
The Medicines Patent Pool (MPP) has announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers …
NICE to recommend three new treatments for hep C
October 16, 2015Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C
NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …
NICE restricts access to new hepatitis C treatments
July 29, 2015Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, daklinza, harvoni, hepatits C
NICE has recommended three new treatment options for hepatitis C in draft guidance – but has been criticised for excluding …
Conference round-up: companies go big on hepatitis C at EASL
April 29, 2015Sales and Marketing Bristol-Myers Squibb, EASL, Merck, daclatasvir, daklinza
Big pharma names posted favourable results for hepatitis C treatments as they jostled for position as market leaders at the …
CHMP approves six drugs including daclatasvir
June 30, 2014Sales and Marketing BMS, CHMP, HCV, Plavix, daclatasvir, daklinza, ge
A key advisory committee for the European Medicines Agency has given its approval to six new drugs at its latest …
